Drug Profile
Turoctocog alfa pegol - Novo Nordisk
Alternative Names: ESPEROCT; Long acting recombinant factor VIII - Novo Nordisk; N8-GP; N8-GP rFVIII; NN 7170; NN-7088; NNC-0129-0000-1003; PEG turoctocog alfa; Pegylated turoctocog alfa; rFVIII glycopegylated - Novo NordiskLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 17 Aug 2023 Novo Nordisk completes the phase-III trial Pathfinder6 in Haemophilia A (In children, In infants, In neonates, Treatment-naive) in USA, Algeria, Argentina, Australia, Austria, Bulgaria, Canada, France, Germany, Greece, Italy, Japan, Malaysia, Portugal, Romania, Spain, Taiwan and Thailand (IV) (NCT02137850) (EudraCT2013-004025-88)
- 05 Jun 2023 Registered for Haemophilia A (Treatment-experienced) in Australia (IV)
- 28 Dec 2022 Novo Nordisk completes the phase III trial Pathfinder10 in Haemophilia A (In adolescents, In adults, Treatment-experienced) in China (IV) (NCT05082116)